Jongen C, Heemsbergen W, Incrocci L, Heijmen B, Rossi L
Cancers (Basel). 2025; 16(24.
PMID: 39766106
PMC: 11674648.
DOI: 10.3390/cancers16244208.
Jongen C, Heijmen B, Schillemans W, Zolnay A, Witte M, Pos F
Clin Transl Radiat Oncol. 2025; 50:100886.
PMID: 39763489
PMC: 11701999.
DOI: 10.1016/j.ctro.2024.100886.
Gao R, Ma J, Pisansky T, Kruse J, Stish B, Kowalchuk R
Int J Part Ther. 2024; 12:100015.
PMID: 38827121
PMC: 11137510.
DOI: 10.1016/j.ijpt.2024.100015.
Liscu H, Antone-Iordache I, Atasiei D, Anghel I, Ilie A, Emamgholivand T
J Pers Med. 2024; 14(3).
PMID: 38541008
PMC: 10971105.
DOI: 10.3390/jpm14030266.
Vieceli M, Park J, Hsi W, Saki M, Mendenhall N, Johnson P
Cancers (Basel). 2024; 16(4).
PMID: 38398171
PMC: 10886728.
DOI: 10.3390/cancers16040780.
Optimizing Clinical Implementation of Hypofractionation: Comprehensive Evidence Synthesis and Practical Guidelines for Low- and Middle-Income Settings.
Starling M, Thibodeau S, de Sousa C, Restini F, Viani G, Gouveia A
Cancers (Basel). 2024; 16(3).
PMID: 38339290
PMC: 10854666.
DOI: 10.3390/cancers16030539.
The march toward single-fraction stereotactic body radiotherapy for localized prostate cancer-Quo Vadimus?.
Ong W, Loblaw A
World J Urol. 2023; 41(12):3485-3491.
PMID: 37921936
DOI: 10.1007/s00345-023-04663-x.
Preliminary Analysis of a Phase II Trial of Stereotactic Body Radiation Therapy for Prostate Cancer With High-Risk Features After Radical Prostatectomy.
Laughlin B, Voss M, Toesca D, Daniels T, Golafshar M, Keole S
Adv Radiat Oncol. 2023; 8(2):101143.
PMID: 36845611
PMC: 9943785.
DOI: 10.1016/j.adro.2022.101143.
Impact of Race on Outcomes of High-Risk Patients With Prostate Cancer Treated With Moderately Hypofractionated Radiotherapy in an Equal Access Setting.
Carpenter D, Natesan D, Floyd R, Oyekunle T, Niedzwiecki D, Waters L
Fed Pract. 2022; 39(Suppl 3):S35-S41.
PMID: 36426110
PMC: 9662313.
DOI: 10.12788/fp.0305.
Stereotactic Radiotherapy after Radical Prostatectomy in Patients with Prostate Cancer in the Adjuvant or Salvage Setting: A Systematic Review.
Schroder C, Tang H, Windisch P, Zwahlen D, Buchali A, Vu E
Cancers (Basel). 2022; 14(3).
PMID: 35158961
PMC: 8833497.
DOI: 10.3390/cancers14030696.
Patient-Reported Quality of Life Outcomes after Moderately Hypofractionated and Normofractionated Proton Therapy for Localized Prostate Cancer.
Nakajima K, Iwata H, Hattori Y, Nomura K, Hayashi K, Toshito T
Cancers (Basel). 2022; 14(3).
PMID: 35158785
PMC: 8833499.
DOI: 10.3390/cancers14030517.
Biologically Targeted Radiation Therapy: Incorporating Patient-Specific Hypoxia Data Derived from Quantitative Magnetic Resonance Imaging.
Her E, Haworth A, Sun Y, Williams S, Reynolds H, Kennedy A
Cancers (Basel). 2021; 13(19).
PMID: 34638382
PMC: 8507789.
DOI: 10.3390/cancers13194897.
Effective Organs-at-Risk Dose Sparing in Volumetric Modulated Arc Therapy Using a Half-Beam Technique in Whole Pelvic Irradiation.
Jang H, Park J, Artz M, Zhang Y, Ricci J, Huh S
Front Oncol. 2021; 11:611469.
PMID: 34490075
PMC: 8416480.
DOI: 10.3389/fonc.2021.611469.
Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial.
Brand D, Bruningk S, Wilkins A, Fernandez K, Naismith O, Gao A
Int J Radiat Oncol Biol Phys. 2021; 110(2):596-608.
PMID: 33412260
PMC: 8129972.
DOI: 10.1016/j.ijrobp.2020.12.041.
Moderately Hypofractionated Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Prostate Cancer: Five-Year Toxicity Results From a Prospective Phase I/II Trial.
Ricco A, Mukhopadhyay N, Deng X, Holdford D, Skinner V, Saraiya S
Front Oncol. 2020; 10:1686.
PMID: 32974208
PMC: 7471868.
DOI: 10.3389/fonc.2020.01686.
SpaceOAR© hydrogel rectal dose reduction prediction model: a decision support tool.
Paetkau O, Gagne I, Alexander A
J Appl Clin Med Phys. 2020; 21(6):15-25.
PMID: 32250042
PMC: 7324696.
DOI: 10.1002/acm2.12860.
Progress towards Patient-Specific, Spatially-Continuous Radiobiological Dose Prescription and Planning in Prostate Cancer IMRT: An Overview.
Her E, Haworth A, Rowshanfarzad P, Ebert M
Cancers (Basel). 2020; 12(4).
PMID: 32244821
PMC: 7226478.
DOI: 10.3390/cancers12040854.
Evaluating the predictive value of quantec rectum tolerance dose suggestions on acute rectal toxicity in prostate carcinoma patients treated with IMRT.
Ozkan E, Ozseven A, Cerkesli Z
Rep Pract Oncol Radiother. 2020; 25(1):50-54.
PMID: 31889921
PMC: 6931199.
DOI: 10.1016/j.rpor.2019.12.002.
A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer.
Kainuma T, Kawakami S, Tsumura H, Satoh T, Tabata K, Iwamura M
Radiat Oncol. 2019; 14(1):158.
PMID: 31477122
PMC: 6720398.
DOI: 10.1186/s13014-019-1369-y.
Hypofractionated Intensity-modulated Radiotherapy for Intermediate- and High-risk Prostate Cancer: A Retrospective Study.
Kubo N, Kawamura H, Oike T, Sato H, Iwanaga M, Mizukami T
In Vivo. 2019; 33(4):1235-1241.
PMID: 31280214
PMC: 6689351.
DOI: 10.21873/invivo.11595.
